These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 11142619

  • 1. Phenotypic HIV-1 resistance correlates with treatment outcome of nelfinavir salvage therapy.
    Walter H, Schmidt B, Rascu A, Helm M, Moschik B, Paatz C, Kurowski M, Korn K, Uberla K, Harrer T.
    Antivir Ther; 2000 Dec; 5(4):249-56. PubMed ID: 11142619
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K.
    Verh K Acad Geneeskd Belg; 2001 Dec; 63(5):447-73. PubMed ID: 11813503
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Impact of genotypic resistance testing on selection of salvage regimen in clinical practice.
    Haupts S, Ledergerber B, Böni J, Schüpbach J, Kronenberg A, Opravil M, Flepp M, Speck RF, Grube C, Rentsch K, Weber R, Günthard HF, Swiss HIV Cohort Study.
    Antivir Ther; 2003 Oct; 8(5):443-54. PubMed ID: 14640392
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Diverse pattern of protease inhibitor resistance mutations in HIV-1 infected patients failing nelfinavir.
    Svedhem V, Lindkvist A, Bergroth T, Knut L, Sönnerborg A.
    J Med Virol; 2005 Aug; 76(4):447-51. PubMed ID: 15977242
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [Abstract] [Full Text] [Related]

  • 10. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
    Rodes B, García F, Gutierrez C, Martinez-Picado J, Aguilera A, Saumoy M, Vallejo A, Domingo P, Dalmau D, Ribas MA, Blanco JL, Pedreira J, Perez-Elias MJ, Leal M, de Mendoza C, Soriano V, Red de Investigación en SIDA.
    J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
    [Abstract] [Full Text] [Related]

  • 11. Salvage therapy for patients failing their current antiretroviral regimen.
    Albrecht MA.
    AIDS Clin Rev; 2005 Sep; ():139-91. PubMed ID: 10999220
    [No Abstract] [Full Text] [Related]

  • 12. Predictive value of drug levels, HIV genotyping, and the genotypic inhibitory quotient (GIQ) on response to saquinavir/ritonavir in antiretroviral-experienced HIV-infected patients.
    Valer L, de Mendoza C, Soriano V.
    J Med Virol; 2005 Dec; 77(4):460-4. PubMed ID: 16254964
    [Abstract] [Full Text] [Related]

  • 13. HIV genotypic resistance testing to optimize antiretroviral prescribing: is there room for improvement?
    Uy J, Brooks JT, Baker R, Hoffman M, Moorman A, Novak R, HOPS Investigators.
    Antivir Ther; 2007 Dec; 12(6):957-62. PubMed ID: 17926650
    [Abstract] [Full Text] [Related]

  • 14. Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containing ritonavir-boosted saquinavir. The CIVSA Study.
    Mallolas J, Blanco J, Labarga P, Vergara A, Ocampo A, Sarasa M, Arnedo M, López-Púa Y, García J, Juega J, Guelar A, Terrón A, Dalmau D, García I, Zárraga M, Martínez E, Carné X, Pumarola T, Escayola R, Gatell J.
    HIV Med; 2007 May; 8(4):226-33. PubMed ID: 17461850
    [Abstract] [Full Text] [Related]

  • 15. A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1-infected patients.
    Van Laethem K, De Luca A, Antinori A, Cingolani A, Perna CF, Vandamme AM.
    Antivir Ther; 2002 Jun; 7(2):123-9. PubMed ID: 12212924
    [Abstract] [Full Text] [Related]

  • 16. Genotypic and phenotypic nevirapine resistance correlates with virological failure during salvage therapy including abacavir and nevirapine.
    Jørgensen LB, Katzenstein TL, Gerstoft J, Mathiesen LR, Pedersen C, Nielsen C.
    Antivir Ther; 2000 Sep; 5(3):187-94. PubMed ID: 11075938
    [Abstract] [Full Text] [Related]

  • 17. Long-term analysis of the resistance development in HIV-1 positive patients treated with protease and reverse transcriptase inhibitors: correlation of the genotype and disease progression.
    Václavíková J, Weber J, Machala L, Reinis M, Linka M, Brůcková M, Vandasová J, Stanková M, Konvalinka J.
    Acta Virol; 2005 Sep; 49(1):29-36. PubMed ID: 15929396
    [Abstract] [Full Text] [Related]

  • 18. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
    Pariente N, Pernas M, de la Rosa R, Gómez-Mariano G, Fernández G, Rubio A, López M, Benito JM, López-Galíndez C, Leal M, Domingo E, Martinez MA, Mas A.
    J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628
    [Abstract] [Full Text] [Related]

  • 19. Drug-resistance mutations in antiretroviral-naïve patients with established HIV-1 infection in Mexico.
    Escoto-Delgadillo M, Vázquez-Valls E, Ramírez-Rodríguez M, Corona-Nakamura A, Amaya-Tapia G, Quintero-Pérez N, Panduro-Cerda A, Torres-Mendoza BM.
    HIV Med; 2005 Nov; 6(6):403-9. PubMed ID: 16268822
    [Abstract] [Full Text] [Related]

  • 20. Effect of antiretroviral triple combinations including the protease inhibitor nelfinavir in heavily pretreated children with HIV-1 infection.
    Hoffmann F, Funk M, Linde R, Notheis G, Petropoulou T, Eberle J, Gürtler L, Belohradsky BH, Wintergerst U.
    Eur J Med Res; 2002 Jul 24; 7(7):330-4. PubMed ID: 12176683
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.